In The News - 2012

HyperBranch Announces Completion of Clinical Enrollment for FDA Pivotal Study

September 24, 2012   |   Durham, NC  

HyperBranch Medical Technology, Inc. announced today that it has completed patient enrollment in the Adherus Dural Sealant U.S. pivotal clinical trial, a controlled, randomized trial comparing the Adherus Dural Sealant in neurosurgery patients, to the only other approved sealant for these procedures. Over 240 patients were treated in the trial. Patients will be followed for four months to evaluate the safety and effectiveness of Adherus, following which, the data will be submitted to the FDA for review as part of the PMA submission.

See Full Press Release

HyperBranch Receives CE Mark for Adherus AutoSpray

May 16,2012   |   Durham, NC  

HyperBranch Medical Technology, Inc. announced today that it has received CE Marking for Adherus AutoSpray Dural Sealant. Adherus AutoSpray is a novel delivery system used for the delivery HyperBranch's dural sealant which is used in cranial and spine surgeries to prevent cerebrospinal fluid leaks following the dural repair.

See Full Press Release